Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

NCT01657591 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: XL888
DRUG: Vemurafenib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]